China’s National Medical Products Administration (NMPA) has approved Zeiss Medical Technology’s retinal imaging system, the ...

Echosens and Boehringer Ingelheim have expanded their collaboration aimed at expediting progress in MASH diagnosis and care.

By combining their diagnostic and therapeutic expertise, Echosens and Boehringer Ingelheim aim to help close persistent gaps ...

A novel canine-specific detection algorithm is designed to improve early identification of heart disease and expand access to life-extending cardiac care for dogsIngelheim, Germany, and San Francisco, ...

This expansion will change the trajectory of MASH by focusing on early detection, diagnosis, and access to care.

Ingelheim: Boehringer Ingelheim and Eko Health have entered a strategic collaboration agreement to improve heart murmur ...

June 10, 2025 | Boehringer Ingelheim, a global leader in animal health, and Eko Health, a pioneer in applying artificial intelligence (AI) for early detection of heart and lung diseases ...

Survodutide is part of Boehringer Ingelheim's research and development portfolio in the cardiovascular, renal and metabolic disease areas. Survodutide is licensed to Boehringer Ingelheim from ...

By combining their diagnostic and therapeutic expertise, Echosens and Boehringer Ingelheim aim to help close persistent gaps in awareness, real-world evidence, and clinical adoption. This next phase ...

Boehringer Ingelheim & Eko Health ink digital health collaboration to improve heart murmur detection in dogs: Ingelheim, Germany Wednesday, June 11, 2025, 10:00 Hrs [IST] Boehring ...

Ingelheim, Germany, and San Francisco, Calif., June 10, 2025 | Boehringer Ingelheim, a global leader in animal health, and Eko Health, a pioneer in applying artificial intelligence (AI ...

By combining their diagnostic and therapeutic expertise, Echosens and Boehringer Ingelheim aim to help close persistent gaps in awareness, real-world evidence, and clinical adoption. This next ...